Medication info
Zepogad Duo Extended-release Tablets 10/500 mg

Zepogad Duo Extended-release Tablets 10/500 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Bis L-proline›15.63mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Cheil Pharmaceutical Co., Ltd.
Appearance
Pink, bilaterally convex, oval film-coated tablets
Packaging
Bottle - 30 tablets/bottle, Box - 30 tablets/box [6 tablets (Alu-Alu) x 5]
Approval status
Active

MFDS item code 202108081 · Approved 2021.12.23 · Insurance code 645406080

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions to metformin. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment with this medicine may be initiated at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering drugs. Since such a change may cause changes in glycemic control, any changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient in this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults).

Ingredients

Manufacturer
Cheil Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar control abnormalities
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This drug works by combining the effects of dapagliflozin and metformin to help control blood sugar in adults with type 2 diabetes. It is particularly used as an adjunct therapy for patients who follow dietary and exercise protocols and is effective even when blood sugar is not adequately controlled. Furthermore, it may affect the occurrence of cardiovascular events in patients with type 2 diabetes who have cardiovascular disease or risk factors, so it should be used safely under the guidance of a healthcare professional. This drug is used to improve blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions to metformin. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment with this medicine may be initiated at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering drugs. Since such a change may cause changes in glycemic control, any changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient in this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults).

Precautions

This drug is a diabetes treatment that helps lower blood sugar. When taking this medication, it should not be used if kidney function is impaired, and kidney function should be regularly monitored. It should be discontinued in conditions that may affect kidney function such as severe infections, dehydration, and acute myocardial infarction. Women who are pregnant or breastfeeding should not take this drug. This medication can lead to a very rare but serious side effect called lactic acidosis. If symptoms such as malaise, muscle pain, respiratory distress, or abdominal pain occur, a doctor should be consulted immediately. This medication may cause hypoglycemia, so when taken along with insulin or other hypoglycemic agents, be aware of the symptoms of hypoglycemia. During the use of this drug, genital infections and urinary tract infections may occur, so if any signs of infection appear, swift treatment is needed. Patients with reduced fluid volume or at risk of low blood pressure should carefully monitor blood pressure and fluid status, adjusting medication if necessary. This medication can lower vitamin B12 levels, so periodic checks of vitamin B12 levels are advised during long-term use. It should be temporarily discontinued before surgery or tests involving iodinated contrast media, resuming after confirming normal kidney function. Excessive alcohol consumption may increase the risk of side effects from this medication, so it should be avoided. Elderly patients are at higher risk of declining kidney function; therefore, dosage adjustments and regular kidney function tests should be performed. This medication has not been established as safe and effective for use in children, thus should not be used in this population. During treatment, dizziness may occur while driving or operating machinery, so caution is advised. Finally, this medication should be stored out of the reach of children and kept in its original container.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 86 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • increased blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendonitis
  • chest pain
  • fever
  • burns
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignancy
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tenosynovitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasions
  • itching
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • neurogenic hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid contact with air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink, bilaterally convex, oval film-coated tablets

Package unit

Bottle - 30 tablets/bottle, Box - 30 tablets/box [6 tablets (Alu-Alu) x 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.